Pharmalink AB Gains Exclusive Licence to Archimedes Pharma's TARGIT(R) Technology for Nefecon(R) (PL-56) Program
12/13/2011 10:13:24 AM
More...
|
Archimedes Pharma Launches Lazanda(R) - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S.
10/17/2011 11:32:08 AM
More...
|
FDA Approves Archimedes Pharma's Lazanda(R) - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
7/1/2011 6:38:49 AM
More...
|
Archimedes Pharma Announces Publication of Long-Term Safety and Tolerability Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in the Journal of Opioid Management
10/12/2010 11:42:09 AM
More...
|
Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain
10/4/2010 7:37:08 AM
More...
|
EC Regulator Rubber-Stamps Archimedes Pharma’s Intranasal Fentanyl Spray for Cancer Pain
9/1/2010 6:24:22 AM
More...
|
Archimedes Pharma Announces New US Headquarters In Bedminster, New Jersey; Archimedes Given Grant To Create Up to 75 New Jobs
8/23/2010 7:57:43 AM
More...
|
Genetic Technologies Limited (GTG.AX) Announces Archimedes Pharma's BREVAGen(TM) Pharmacoeconomic Data Presented at American Society of Clinical Oncology 2010 in Chicago
6/8/2010 10:58:32 AM
More...
|
Private UK Drug Firm Archimedes Pharma Raises US $100 Million; Former Enzon Pharmaceuticals, Inc. (ENZN) Head Appointed as CEO; US Commercial Operations to be Established
3/2/2010 6:57:09 AM
More...
|
Archimedes Pharma Announces US Filing of NasalFent(R) for the treatment of Breakthrough Cancer Pain
9/8/2009 2:06:32 PM
More...
|
|